Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development

Abstract

Polo-like kinase 1 (Plk1), a well-characterized member of serine/threonine kinases Plk family, has been shown to play pivotal roles in mitosis and cytokinesis in eukaryotic cells. Recent studies suggest that Plk1 not only controls the process of mitosis and cytokinesis, but also, going beyond those previously described functions, plays critical roles in DNA replication and Pten null prostate cancer initiation. In this review, we briefly summarize the functions of Plk1 in mitosis and cytokinesis, and then mainly focus on newly discovered functions of Plk1 in DNA replication and in Ptennull prostate cancer initiation. Furthermore, we briefly introduce the architectures of human and mouse prostate glands and the possible roles of Plk1 in human prostate cancer development. And finally, the newly chemotherapeutic development of small-molecule Plk1 inhibitors to target Plk1 in cancer treatment and their translational studies are also briefly reviewed.

Keywords

polo-like kinase 1 / cell cycle regulation / Orc2 / DNA replication / early embryonic development / prostate cancer / Pten / cancer initiation and progression / translational studies

References

[1] Ahmad, N. (2004). Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer. FASEB J 18, 5-7 .10.1096/fj.03-0848hyp
[2] Ahonen, L.J., Kallio, M.J., Daum, J.R., Bolton, M., Manke, I.A., Yaffe, M.B.,Stukenberg, P.T., and Gorbsky, G.J. (2005). Polo-like kinase 1 creates the tension-sensing 3F3/2 phosphoepitope and modulates the association of spindle-checkpoint proteins at kinetochores. Curr Biol 15, 1078-1089 .10.1016/j.cub.2005.05.026
[3] American Cancer Society. (2009). Cancer facts & figures 2009. American Cancer Society, Atlanta, GA .
[4] Andrysik, Z., Bernstein, W.Z., Deng, L., Myer, D.L., Li, Y.-Q., Tischfield, J.A., Stambrook, P.J., and Bahassi, M. (2010). The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus. Nucleic Acids Res 38, 2931-2943 .10.1093/nar/gkq011
[5] Archambault, V., and Glover, D.M. (2009). Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 10, 265-275 .10.1038/nrm2653
[6] Bahassi el, M. (2011). Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions. Exp Biol Med 236, 648-657 .10.1258/ebm.2011.011011
[7] Barr, F.A., and Gruneberg, U. (2007). Cytokinesis: placing and making the final cut. Cell 131, 847-860 .10.1016/j.cell.2007.11.011
[8] Barr, F.A., Silljé, H.H., and Nigg, E.A. (2004). Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 5, 429-440 .10.1038/nrm1401
[9] Bartsch, G., Frick, J., Rüegg, I., Bucher, M., Holliger, O., Oberholzer, M., and Rohr, H.P. (1979). Electron microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 122, 481-486 .
[10] Bell, S.P., and Dutta, A. (2002). DNA replication in eukaryotic cells. Annu Rev Biochem 71, 333-374 .10.1146/annurev.biochem.71.110601.135425
[11] Bell, S.P., and Stillman, B. (1992). ATP-dependent recognition of eukaryotic origins of DNA replication by a multiprotein complex. Nature 357, 128-134 .10.1038/357128a0
[12] Berquin, I.M., Min, Y., Wu, R., Wu, H., and Chen, Y.Q. (2005). Expression signature of the mouse prostate. J Biol Chem 280, 36442-36451 .10.1074/jbc.M504945200
[13] Blow, J.J., and Dutta, A. (2005). Preventing re-replication of chromosomal DNA. Nat Rev Mol Cell Biol 6, 476-486 .10.1038/nrm1663
[14] Bonkhoff, H., Wernert, N., Dhom, G., and Remberger, K. (1991). Basement membranes in fetal, adult normal, hyperplastic and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol 418, 375-381 .10.1007/BF01605922
[15] Bonkhoff, H., Wernert, N., Dhom, G., and Remberger, K. (1992). Distribution of basement membranes in primary and metastatic carcinomas of the prostate. Hum Pathol 23, 934-93 .10.1016/0046-8177(92)90408-U
[16] Brawer, M.K., Peehl, D.M., Stamey, T.A., and Bostwick, D.G. (1985). Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res 45, 3663-3667 .
[17] Burkard, M.E., Maciejowski, J., Rodriguez-Bravo, V., Repka, M., Lowery, D.M., Clauser, K.R., Zhang, C., Shokat, K.M., Carr, S.A., Yaffe, M.B., . (2009). Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells. PLoS Biol 7, e1000111.10.1371/journal.pbio.1000111
[18] Carver, B.S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V.K., Le, C., Koutcher, J., Scher, H., . (2011). Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575-586 .10.1016/j.ccr.2011.04.008
[19] Casenghi, M., Barr, F.A., and Nigg, E.A. (2005). Phosphorylation of Nlp by Plk1 negatively regulates its dynein-dynactin-dependent targeting to the centrosome. J Cell Sci 118, 5101-5108 .10.1242/jcs.02622
[20] Casenghi, M., Meraldi, P., Weinhart, U., Duncan, P.I., K?rner, R., and Nigg, E.A. (2003). Polo-like kinase 1 regulates Nlp, a centrosome protein involved in microtubule nucleation. Dev Cell 5, 113-125 .10.1016/S1534-5807(03)00193-X
[21] Cheng, K.-Y., Lowe, E.D., Sinclair, J., Nigg, E.A., and Johnson, L.N. (2003). The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex. EMBO J 22, 5757-5768 .10.1093/emboj/cdg558
[22] Clay, F.J., McEwen, S.J., Bertoncello, I., Wilks, A.F., and Dunn, A.R. (1993). Identification and cloning of a protein kinase-encoding mouse gene, Plk, related to the polo gene of Drosophila. Proc Natl Acad Sci U S A 90, 4882-4886 .10.1073/pnas.90.11.4882
[23] Eckerdt, F., and Strebhardt, K. (2006). Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis. Cancer Res 66, 6895-6898 .10.1158/0008-5472.CAN-06-0358
[24] Eckerdt, F., Yuan, J., and Strebhardt, K. (2005). Polo-like kinases and oncogenesis. Oncogene 24, 267-276 .10.1038/sj.onc.1208273
[25] EI Sheikh, S.S., Romanska, H.M., Abel, P., Domin, J., and Lalani, N. (2008). Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer—a pilot study. Neoplasia 10, 949-953 .
[26] Elia, A.E., Cantley, L.C., and Yaffe, M.B. (2003a). Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science 299, 1228-1231 .10.1126/science.1079079
[27] Elia, A.E.H., Rellos, P., Haire, L.F., Chao, J.W., Ivins, F.J., Hoepker, K., Mohammad, D., Cantley, L.C., Smerdon, S.J., and Yaffe, M.B. (2003b). The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 115, 83-95 .10.1016/S0092-8674(03)00725-6
[28] Elowe, S., Hümmer, S., Uldschmid, A., Li, X., and Nigg, E.A. (2007). Tension-sensitive Plk1 phosphorylation on BubR1 regulates the stability of kinetochore microtubule interactions. Genes Dev 21, 2205-2219 .10.1101/gad.436007
[29] Foster, C.S., Dodson, A., Karavana, V., Smith, P.H., and Ke, Y. (2002). Prostatic stem cells. J Pathol 197, 551-565 .10.1002/path.1194
[30] Galgoczy, D.J., and Toczyski, D.P. (2001). Checkpoint adaptation precedes spontaneous and damage-induced genomic instability in yeast. Mol Cell Biol 21, 1710-1718 .10.1128/MCB.21.5.1710-1718.2001
[31] Gandhi, L., Chu, Q.S., Stephenson, J., . (2009). An open label phase II trial of the Plk1 inhibitor BI 2536, in patients with sensitive relapsed small cell lung cancer (SCLC). J Clin Oncol , 27. [abstract 8108]
[32] Gao, H., Ouyang, X., Banach-Petrosky, W.A., Shen, M.M., and Abate-Shen, C. (2006). Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. Cancer Res 66, 7929-7933 .10.1158/0008-5472.CAN-06-1637
[33] Garland, L.L., Taylor, C., Pilkington, D.L., Cohen, J.L., and Von Hoff, D.D. (2006). A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res 12, 5182-5189 .10.1158/1078-0432.CCR-06-0214
[34] Giordano-Coltart, J., Ying, C.Y., Gautier, J., and Hurwitz, J. (2005). Studies of the properties of human origin recognition complex and its Walker A motif mutants. Proc Natl Acad Sci U S A 102, 69-74 .10.1073/pnas.0408690102
[35] Glover, D.M., Hagan, I.M., and Tavares, A.A.M. (1998). Polo-like kinases: a team that plays throughout mitosis. Genes Dev 12, 3777-3787 .10.1101/gad.12.24.3777
[36] Golsteyn, R.M., Mundt, K.E., Fry, A.M., and Nigg, E.A. (1995). Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J Cell Biol 129, 1617-1628 .10.1083/jcb.129.6.1617
[37] Golsteyn, R.M., Schultz, S.J., Bartek, J., Ziemiecki, A., Ried, T., and Nigg, E.A. (1994). Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci 107, 1509-1517 .
[38] Goto, H., Kiyono, T., Tomono, Y., Kawajiri, A., Urano, T., Furukawa, K., Nigg, E.A., and Inagaki, M. (2006). Complex formation of Plk1 and INCENP required for metaphase-anaphase transition. Nat Cell Biol 8, 180-187 .10.1038/ncb1350
[39] Gray, P.J. Jr, Bearss, D.J., Han, H., Nagle, R., Tsao, M.-S., Dean, N., and Von Hoff, D.D. (2004). Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 3, 641-646 .
[40] Guan, R., Tapang, P., Leverson, J.D., Albert, D., Giranda, V.L., and Luo, Y. (2005). Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 65, 2698-2704 .10.1158/0008-5472.CAN-04-2131
[41] Gumireddy, K., Reddy, M.V., Cosenza, S.C., Boominathan, R., Baker, S.J., Papathi, N., Jiang, J., Holland, J., and Reddy, E.P. (2005). ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7, 275-286 .10.1016/j.ccr.2005.02.009
[42] Hanisch, A., Wehner, A., Nigg, E.A., and Silljé, H.H. (2006). Different Plk1 functions show distinct dependencies on Polo-Box domain-mediated targeting. Mol Biol Cell 17, 448-459 .10.1091/mbc.E05-08-0801
[43] Hansen, D.V., Loktev, A.V., Ban, K.H., and Jackson, P.K. (2004). Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC Inhibitor Emi1. Mol Biol Cell 15, 5623-5634 .10.1091/mbc.E04-07-0598
[44] Hudson, D.L. (2004). Epithelial stem cells in human prostate growth and disease. Prostate Cancer Prostatic Dis 7, 188-194 .10.1038/sj.pcan.4500745
[45] Hudson, J.W., Kozarova, A., Cheung, P., Macmillan, J.C., Swallow, C.J., Cross, J.C., and Dennis, J.W. (2001). Late mitotic failure in mice lacking Sak, a polo-like kinase. Curr Biol 11, 441-446 .10.1016/S0960-9822(01)00117-8
[46] Iizuka, M., and Stillman, B. (1999). Histone acetyltransferase HBO1 interacts with the ORC1 subunit of the human initiator protein. J Biol Chem 274, 23027-23034 .10.1074/jbc.274.33.23027
[47] Inoue, D., and Sagata, N. (2005). The Polo-like kinase Plx1 interacts with and inhibits Myt1 after fertilization of Xenopus eggs. EMBO J 24, 1057-1067 .10.1038/sj.emboj.7600567
[48] Ito, Y., Miyoshi, E., Sasaki, N., Kakudo, K., Yoshida, H., Tomoda, C., Uruno, T., Takamura, Y., Miya, A., Kobayashi, K., . (2004). Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma. Br J Cancer 90, 414-418 .10.1038/sj.bjc.6601540
[49] Jackman, M., Lindon, C., Nigg, E.A., and Pines, J. (2003). Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat Cell Biol 5, 143-148 .10.1038/ncb918
[50] Jeong, K., Jeong, J.Y., Lee, H.O., Choi, E., and Lee, H. (2010). Inhibition of Plk1 induces mitotic infidelity and embryonic growth defects in developing zebrafish embryos. Dev Biol 345, 34-48 .10.1016/j.ydbio.2010.06.004
[51] Jiao, J., Wang, S., Qiao, R., Vivanco, I., Watson, P.A., Sawyers, C.L., and Wu, H. (2007). Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 67, 6083-6091 .10.1158/0008-5472.CAN-06-4202
[52] Jimeno, A., Li, J., Messersmith, W.A., Laheru, D., Rudek, M.A., Maniar, M., Hidalgo, M., Baker, S.D., and Donehower, R.C. (2008). Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 26, 5504-5510 .10.1200/JCO.2008.17.9788
[53] Johnson, E.F., Stewart, K.D., Woods, K.W., Giranda, V.L., and Luo, Y. (2007). Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity. Biochemistry 46, 9551-9563 .10.1021/bi7008745
[54] Kang, Y.H., Park, J.-E., Yu, L.-R., Soung, N.-K., Yun, S.-M., Bang, J.K., Seong, Y.-S., Yu, H., Garfield, S., Veenstra, T.D., . (2006). Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation. Mol Cell 24, 409-422 .10.1016/j.molcel.2006.10.016
[55] Knecht, R., Elez, R., Oechler, M., Solbach, C., von Ilberg, C., and Strebhardt, K. (1999). Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 59, 2794-2797 .
[56] Knecht, R., Oberhauser, C., and Strebhardt, K. (2000). PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int J Cancer 89, 535-536 .10.1002/1097-0215(20001120)89:6<535::AID-IJC12>3.0.CO;2-E
[57] Knudsen, B.S., and Vasioukhin, V. (2010). Mechanisms of prostate cancer initiation and progression. Adv Cancer Res 109, 1-50 .10.1016/B978-0-12-380890-5.00001-6
[58] Kothe, M., Kohls, D., Low, S., Coli, R., Cheng, A.C., Jacques, S.L., Johnson, T.L., Lewis, C., Loh, C., Nonomiya, J., . (2007a). Structure of the catalytic domain of human polo-like kinase 1. Biochemistry 46, 5960-5971 .10.1021/bi602474j
[59] Kothe, M., Kohls, D., Low, S., Coli, R., Rennie, G.R., Feru, F., Kuhn, C., and Ding, Y.H. (2007b). Selectivity-determining residues in Plk1. Chem Biol Drug Des 70, 540-546 .10.1111/j.1747-0285.2007.00594.x
[60] Kumagai, A., and Dunphy, W.G. (1996). Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Science 273, 1377-1380 .10.1126/science.273.5280.1377
[61] Kumagai, A., and Dunphy, W.G. (2003). Repeated phosphopeptide motifs in Claspin mediate the regulated binding of Chk1. Nat Cell Biol 5, 161-165 .10.1038/ncb921
[62] Lake, R.J., and Jelinek, W.R. (1993). Cell cycle- and terminal differentiation-associated regulation of the mouse mRNA encoding a conserved mitotic protein kinase. Mol Cell Biol 13, 7793-7801 .
[63] Lane, H.A., and Nigg, E.A. (1996). Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 135, 1701-1713 .10.1083/jcb.135.6.1701
[64] Lee, K.S., Park, J.-E., Kang, Y.H., Zimmerman, W., Soung, N.-K., Seong, Y.-S., Kwak, S.-J., and Erikson, R.L. (2008). Mechanisms of mammalian polo-like kinase 1 (Plk1) localization: self- versus non-self-priming. Cell Cycle 7, 141-145 .10.4161/cc.7.2.5272
[65] Lee, K.S., Yuan, Y.L., Kuriyama, R., and Erikson, R.L. (1995). Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. Mol Cell Biol 15, 7143-7151 .
[66] Lee, S.E., Pellicioli, A., Malkova, A., Foiani, M., and Haber, J.E. (2001). The Saccharomyces recombination protein Tid1p is required for adaptation from G2/M arrest induced by a double-strand break. Curr Biol 11, 1053-1057 .10.1016/S0960-9822(01)00296-2
[67] Lénárt, P., Petronczki, M., Steegmaier, M., Di Fiore, B., Lipp, J.J., Hoffmann, M., Rettig, W.J., Kraut, N., and Peters, J.-M. (2007). The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 17, 304-315 .10.1016/j.cub.2006.12.046
[68] Li, H., Liu, X.S., Yang, X., Song, B., Wang, Y., and Liu, X. (2010b). Polo-like kinase 1 phosphorylation of p150^Glued facilitates nuclear envelope breakdown during prophase. Proc Natl Acad Sci U S A 107, 14633-14638 .10.1073/pnas.1006615107
[69] Li, H., Liu, X.S., Yang, X., Wang, Y., Wang, Y., Turner, J.R., and Liu, X. (2010a). Phosphorylation of CLIP-170 by Plk1 and CK2 promotes timely formation of kinetochore-microtubule attachments. EMBO J 29, 2953-2965 .10.1038/emboj.2010.174
[70] Li, H., Wang, Y., and Liu, X. (2008). Plk1-dependent phosphorylation regulates functions of DNA topoisomerase IIalpha in cell cycle progression. J Biol Chem 283, 6209-6221 .10.1074/jbc.M709007200
[71] Liang, C., Weinreich, M., and Stillman, B. (1995). ORC and Cdc6p interact and determine the frequency of initiation of DNA replication in the genome. Cell 81, 667-676 .10.1016/0092-8674(95)90528-6
[72] Liu, A.Y., True, L.D., LaTray, L., Nelson, P.S., Ellis, W.J., Vessella, R.L., Lange, P.H., Hood, L., and van den Engh, G. (1997). Cellcell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci U S A 94, 10705-10710 .10.1073/pnas.94.20.10705
[73] Liu, X., and Erikson, R.L. (2003). Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A 100, 5789-5794 .10.1073/pnas.1031523100
[74] Liu, X., Zhou, T., Kuriyama, R., and Erikson, R.L. (2004). Molecular interactions of Polo-like-kinase 1 with the mitotic kinesin-like protein CHO1/MKLP-1. J Cell Sci 117, 3233-3246 .10.1242/jcs.01173
[75] Liu, X.S., Li, H., Song, B., and Liu, X. (2010a). Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery. EMBO Rep 11, 626-632 .10.1038/embor.2010.90
[76] Liu, X.S., Song, B., Elzey, B.D., Ratliff, T.L., Konieczny, S.F., Cheng, L., Ahmad, N., and Liu, X. (2011). Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation. J Biol Chem 286, 35795-35800 .10.1074/jbc.C111.269050
[77] Liu, X.S., Song, B., and Liu, X. (2010b). The substrates of Plk1, beyond the functions in mitosis. Protein Cell 1, 999-1010 .10.1007/s13238-010-0131-x
[78] Llamazares, S., Moreira, A., Tavares, A., Girdham, C., Spruce, B.A., Gonzalez, C., Karess, R.E., Glover, D.M., and Sunkel, C.E. (1991). polo encodes a protein kinase homolog required for mitosis in Drosophila. Genes Dev 5, 2153-2165 .10.1101/gad.5.12a.2153
[79] Lu, L.Y., Wood, J.L., Minter-Dykhouse, K., Ye, L., Saunders, T.L., Yu, X., and Chen, J. (2008). Polo-like kinase 1 is essential for early embryonic development and tumor suppression. Mol Cell Biol 28, 6870-6876 .10.1128/MCB.00392-08
[80] Ma, S., Charron, J., and Erikson, R.L. (2003). Role of Plk2 (Snk) in mouse development and cell proliferation. Mol Cell Biol 23, 6936-6943 .10.1128/MCB.23.19.6936-6943.2003
[81] Macmillan, J.C., Hudson, J.W., Bull, S., Dennis, J.W., and Swallow, C.J. (2001). Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer. Ann Surg Oncol 8, 729-740 .10.1007/s10434-001-0729-6
[82] Manke, I.A., Lowery, D.M., Nguyen, A., and Yaffe, M.B. (2003). BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science 302, 636-639 .10.1126/science.1088877
[83] Martin, B.T., and Strebhardt, K. (2006). Polo-like kinase 1: target and regulator of transcriptional control. Cell Cycle 5, 2881-2885 .10.4161/cc.5.24.3538
[84] Masai, H., Matsumoto, S., You, Z., Yoshizawa-Sugata, N., and Oda, M. (2010). Eukaryotic chromosome DNA replication: where, when, and how? Annu Rev Biochem 79, 89-130 .10.1146/annurev.biochem.052308.103205
[85] McNeal, J.E. (1969). Origin and development of carcinoma in the prostate. Cancer 23, 24-34 .10.1002/1097-0142(196901)23:1<24::AID-CNCR2820230103>3.0.CO;2-1
[86] McNeal, J.E. (1981). The zonal anatomy of the prostate. Prostate 2, 35-49 .10.1002/pros.2990020105
[87] McNeal, J.E. (1988). Normal histology of the prostate. Am J Surg Pathol 12, 619-633 .10.1097/00000478-198808000-00003
[88] Moshe, Y., Boulaire, J., Pagano, M., and Hershko, A. (2004). Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proc Natl Acad Sci U S A 101, 7937-7942 .10.1073/pnas.0402442101
[89] Mross, K., Frost, A., Steinbild, S., Hedbom, S., Rentschler, J., Kaiser, R., Rouyrre, N., Trommeshauser, D., Hoesl, C.E., and Munzert, G. (2008). Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 26, 5511-5517 .10.1200/JCO.2008.16.1547
[90] Nagle, R.B., Ahmann, F.R., McDaniel, K.M., Paquin, M.L., Clark, V.A., and Celniker, A. (1987). Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res 47, 281-286 .
[91] Nakajima, H., Toyoshima-Morimoto, F., Taniguchi, E., and Nishida, E. (2003). Identification of a consensus motif for Plk (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate. J Biol Chem 278, 25277-25280 .10.1074/jbc.C300126200
[92] Neef, R., Gruneberg, U., Kopajtich, R., Li, X., Nigg, E.A., Sillje, H., and Barr, F.A. (2007). Choice of Plk1 docking partners during mitosis and cytokinesis is controlled by the activation state of Cdk1. Nat Cell Biol 9, 436-444 .10.1038/ncb1557
[93] Niiya, F., Tatsumoto, T., Lee, K.S., and Miki, T. (2006). Phosphorylation of the cytokinesis regulator ECT2 at G2/M phase stimulates association of the mitotic kinase Plk1 and accumulation of GTP-bound RhoA. Oncogene 25, 827-837 .10.1038/sj.onc.1209124
[94] Nishimura, Y., and Yonemura, S. (2006). Centralspindlin regulates ECT2 and RhoA accumulation at the equatorial cortex during cytokinesis. J Cell Sci 119, 104-114 .10.1242/jcs.02737
[95] Nishino, M., Kurasawa, Y., Evans, R., Lin, S.-H., Brinkley, B.R., and Yu-Lee, L.Y. (2006). NudC is required for Plk1 targeting to the kinetochore and chromosome congression. Curr Biol 16, 1414-1421 .10.1016/j.cub.2006.05.052
[96] Olmos, D., Allred, A., Sharma, R., . (2009). Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors. J Clin Oncol , 27. [abstract 3536]
[97] Oshimori, N., Ohsugi, M., and Yamamoto, T. (2006). The Plk1 target Kizuna stabilizes mitotic centrosomes to ensure spindle bipolarity. Nat Cell Biol 8, 1095-1101 .10.1038/ncb1474
[98] Pandha, H.S., Protheroe, A., Wylie, J., . (2008). An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol , 26 [abstract 14547]
[99] Park, J.E., Soung, N.K., Johmura, Y., Kang, Y.H., Liao, C., Lee, K.H., Park, C.H., Nicklaus, M.C., and Lee, K.S. (2010). Polo-box domain: a versatile mediator of polo-like kinase function. Cell Mol Life Sci 67, 1957-1970 .10.1007/s00018-010-0279-9
[100] Patnaik, A., Forero, L., Goetz, A.. (2003). HMN-214, a novel oral antimicrotubular agent and inhibitor of Polo-like- and cyclin-dependent kinases: Clinical, pharmacokinetic (PK) and pharmacodynamic (PD) relationships observed in a phase I trial of a daily x 5 schedule every 28 days. Proc Am Soc Clin Oncol 22, 514.
[101] Pavicic-Kaltenbrunner, V., Mishima, M., and Glotzer, M. (2007). Cooperative assembly of CYK-4/MgcRacGAP and ZEN-4/MKLP1 to form the centralspindlin complex. Mol Biol Cell 18, 4992-5003 .10.1091/mbc.E07-05-0468
[102] Peehl, D.M. (2005). Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer 12, 19-47 .10.1677/erc.1.00795
[103] Petronczki, M., Lénárt, P., and Peters, J.M. (2008). Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. Dev Cell 14, 646-659 .10.1016/j.devcel.2008.04.014
[104] Qi, W., Tang, Z., and Yu, H. (2006). Phosphorylation- and polo-boxdependent binding of Plk1 to Bub1 is required for the kinetochore localization of Plk1. Mol Biol Cell 17, 3705-3716 .10.1091/mbc.E06-03-0240
[105] Reagan-Shaw, S., and Ahmad, N. (2005a). Polo-like kinase (Plk) 1 as a target for prostate cancer management. IUBMB Life 57, 677-682 .10.1080/15216540500305910
[106] Reagan-Shaw, S., and Ahmad, N. (2005b). Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. The FASEB J 19, 611-613 .
[107] Reid, A.H.M., Attard, G., Ambroisine, L., Fisher, G., Kovacs, G., Brewer, D., Clark, J., Flohr, P., Edwards, S., Berney, D.M., , and the Transatlantic Prostate Group. (2010). Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 102, 678-684 .10.1038/sj.bjc.6605554
[108] Reindl, W., Strebhardt, K., and Berg, T. (2008b). A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1. Anal Biochem 383, 205-209 .10.1016/j.ab.2008.08.014
[109] Reindl, W., Yuan, J., Kr?mer, A., Strebhardt, K., and Berg, T. (2008a). Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol 15, 459-466 .10.1016/j.chembiol.2008.03.013
[110] Reindl, W., Yuan, J., Kr?mer, A., Strebhardt, K., and Berg, T. (2009). A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. Chembiochem 10, 1145-1148 .10.1002/cbic.200900059
[111] Rosasco-Nitcher, S.E., Lan, W., Khorasanizadeh, S., and Stukenberg, P.T. (2008). Centromeric Aurora-B activation requires TD-60, microtubules, and substrate priming phosphorylation. Science 319, 469-472 .10.1126/science.1148980
[112] Santamaria, A., Neef, R., Ebersp?cher, U., Eis, K., Husemann, M., Mumberg, D., Prechtl, S., Schulze, V., Siemeister, G., Wortmann, L., . (2007). Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell 18, 4024-4036 .10.1091/mbc.E07-05-0517
[113] Sebastian, M., Reck, M., Digel, W., . (2009). Impact of BI2536, a novel Plk1 inhibitor, on disease progression and quality of life parameters in patients with non-small cell lung cancer: results of a randomized phase II trial. Ann Oncol , 19. [abstract 295]
[114] Sehnoy, A., Pfannes, L., Wilhelm, F., . (2008). Suppression of cyclin D 1(CD1) by ON 01910.Na is associated with decreased survival or trisomy 8 myelodysplastic bone marrow: a potential targeted therapy for trisomy 8 MDS. Blood , 112. [abstract 1651]
[115] Shappell, S.B., Thomas, G.V., Roberts, R.L., Herbert, R., Ittmann, M.M., Rubin, M.A., Humphrey, P.A., Sundberg, J.P., Rozengurt, N., Barrios, R., , and the The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. (2004). Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64, 2270-2305 .10.1158/0008-5472.CAN-03-0946
[116] Shen, M.M., and Abate-Shen, C. (2010). Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 24, 1967-2000 .10.1101/gad.1965810
[117] Shirayama, M., Zachariae, W., Ciosk, R., and Nasmyth, K. (1998). The Polo-like kinase Cdc5p and the WD-repeat protein Cdc20p/fizzy are regulators and substrates of the anaphase promoting complex in Saccharomyces cerevisiae. EMBO J 17, 1336-1349 .10.1093/emboj/17.5.1336
[118] Smith, M.R., Wilson, M.L., Hamanaka, R., Chase, D., Kung, H., Longo, D.L., and Ferris, D.K. (1997). Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 234, 397-405 .10.1006/bbrc.1997.6633
[119] Somers, W.G., and Saint, R. (2003). A RhoGEF and Rho family GTPase-activating protein complex links the contractile ring to cortical microtubules at the onset of cytokinesis. Dev Cell 4, 29-39 .10.1016/S1534-5807(02)00402-1
[120] Song, B., Liu, X.S., Davis, K., and Liu, X. (2011). Plk1 phosphorylation of Orc2 promotes DNA replication under conditions of stress. Mol Cell Biol 31, 4844-4856 .10.1128/MCB.06110-11
[121] Sp?nkuch, B., Matthess, Y., Knecht, R., Zimmer, B., Kaufmann, M., and Strebhardt, K. (2004). Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 96, 862-872 .10.1093/jnci/djh146
[122] Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krssák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., . (2007). BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17, 316-322 .10.1016/j.cub.2006.12.037
[123] Strebhardt, K. (2010). Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9, 643-660 .10.1038/nrd3184
[124] Strebhardt, K., Kneisel, L., Linhart, C., Bernd, A., and Kaufmann, R. (2000). Prognostic value of pololike kinase expression in melanomas. JAMA 283, 479-480 .10.1001/jama.283.4.479
[125] Strebhardt, K., and Ullrich, A. (2006). Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6, 321-330 .10.1038/nrc1841
[126] Stuermer, A., Hoehn, K., Faul, T., Auth, T., Brand, N., Kneissl, M., Pütter, V., and Grummt, F. (2007). Mouse pre-replicative complex proteins colocalise and interact with the centrosome. Eur J Cell Biol 86, 37-50 .10.1016/j.ejcb.2006.09.002
[127] Sylju?sen, R.G., Jensen, S., Bartek, J., and Lukas, J. (2006). Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases. Cancer Res 66, 10253-10257 .10.1158/0008-5472.CAN-06-2144
[128] Takahashi, T., Sano, B., Nagata, T., Kato, H., Sugiyama, Y., Kunieda, K., Kimura, M., Okano, Y., and Saji, S. (2003). Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 94, 148-152 .10.1111/j.1349-7006.2003.tb01411.x
[129] Takai, N., Hamanaka, R., Yoshimatsu, J., and Miyakawa, I. (2005). Polo-like kinases (Plks) and cancer. Oncogene 24, 287-291 .10.1038/sj.onc.1208272
[130] Takai, N., Miyazaki, T., Fujisawa, K., Nasu, K., Hamanaka, R., and Miyakawa, I. (2001a). Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett 164, 41-49 .10.1016/S0304-3835(00)00703-5
[131] Takai, N., Miyazaki, T., Fujisawa, K., Nasu, K., Hamanaka, R., and Miyakawa, I. (2001b). Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett 169, 41-49 .10.1016/S0304-3835(01)00522-5
[132] Takaki, T., Trenz, K., Costanzo, V., and Petronczki, M. (2008). Polo-like kinase 1 reaches beyond mitosis—cytokinesis, DNA damage response, and development. Curr Opin Cell Biol 20, 650-660 .10.1016/j.ceb.2008.10.005
[133] Taylor, B.S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B.S., Arora, V.K., Kaushik, P., Cerami, E., Reva, B., . (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 .10.1016/j.ccr.2010.05.026
[134] Timms, B.G. (2008). Prostate development: a historical perspective. Differentiation 76, 565-577 .10.1111/j.1432-0436.2008.00278.x
[135] Toczyski, D.P., Galgoczy, D.J., and Hartwell, L.H. (1997). CDC5 and CKII control adaptation to the yeast DNA damage checkpoint. Cell 90, 1097-1106 .10.1016/S0092-8674(00)80375-X
[136] Tokumitsu, Y., Mori, M., Tanaka, S., Akazawa, K., Nakano, S., and Niho, Y. (1999). Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int J Oncol 15, 687-692 .
[137] Toyoshima-Morimoto, F., Taniguchi, E., and Nishida, E. (2002). Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep 3, 341-348 .10.1093/embo-reports/kvf069
[138] Toyoshima-Morimoto, F., Taniguchi, E., Shinya, N., Iwamatsu, A., and Nishida, E. (2001). Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 410, 215-220 .10.1038/35065617
[139] Tsvetkov, L., and Stern, D.F. (2005). Interaction of chromatin-associated Plk1 and Mcm7. J Biol Chem 280, 11943-11947 .10.1074/jbc.M413514200
[140] van de Weerdt, B.C., and Medema, R.H. (2006). Polo-like kinases: a team in control of the division. Cell Cycle 5, 853-864 .10.4161/cc.5.8.2692
[141] van Leenders, G.J.L.H., and Schalken, J.A. (2003). Epithelial cell differentiation in the human prostate epithelium: implications for the pathogenesis and therapy of prostate cancer. Crit Rev Oncol Hematol 46, S3-S10 .10.1016/S1040-8428(03)00059-3
[142] van Vugt, M.A.T.M., Gardino, A.K., Linding, R., Ostheimer, G.J., Reinhardt, H.C., Ong, S.-E., Tan, C.S., Miao, H., Keezer, S.M., Li, J., . (2010). A mitotic phosphorylation feedback network connects Cdk1, Plk1, 53BP1, and Chk2 to inactivate the G(2)/M DNA damage checkpoint. PLoS Biol 8, e1000287.10.1371/journal.pbio.1000287
[143] von Hoff, D.D., Taylor, C., Rubin, S., . (2004). A phase I and pharmacokinetic study of HMN-214, a novel oral Polo-like kinase inhibitor, in patients with advanced solid tumors. [abstract] J Clin Oncol 22, 3034.
[144] Vose, J., Young, A., Friedberg, J.W., . (2008). Phase I dose-escalation trial of BI 2536, a polo-like kinase 1 inhibitor, in relapsed and refractory Non-Hodgkin's lymphoma. Blood 112. [abstract 233]
[145] W?sch, R., and Engelbert, D. (2005). Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene 24, 1-10 .10.1038/sj.onc.1208017
[146] Watanabe, N., Arai, H., Nishihara, Y., Taniguchi, M., Watanabe, N., Hunter, T., and Osada, H. (2004). M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. Proc Natl Acad Sci U S A 101, 4419-4424 .10.1073/pnas.0307700101
[147] Watanabe, N., Sekine, T., Takagi, M., Iwasaki, J., Imamoto, N.,Kawasaki, H., and Osada, H. (2009). Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. J Biol Chem 284, 2344-2353 .10.1074/jbc.M805308200
[148] Weichert, W., Denkert, C., Schmidt, M., Gekeler, V., Wolf, G., K?bel, M., Dietel, M., and Hauptmann, S. (2004a). Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 90, 815-821 .10.1038/sj.bjc.6601610
[149] Weichert, W., Schmidt, M., Gekeler, V., Denkert, C., Stephan, C., Jung, K., Loening, S., Dietel, M., and Kristiansen, G. (2004b). Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 60, 240-245 .10.1002/pros.20050
[150] Wolf, G., Elez, R., Doermer, A., Holtrich, U., Ackermann, H., Stutte, H.J., Altmannsberger, H.M., Rübsamen-Waigmann, H., and Strebhardt, K. (1997). Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 14, 543-549 .10.1038/sj.onc.1200862
[151] Wolf, G., Hildenbrand, R., Schwar, C., Grobholz, R., Kaufmann, M., Stutte, H.J., Strebhardt, K., and Bleyl, U. (2000). Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract 196, 753-759 .
[152] Wolfe, B.A., Takaki, T., Petronczki, M., and Glotzer, M. (2009). Polo-like kinase 1 directs assembly of the HsCyk-4 RhoGAP/Ect2 RhoGEF complex to initiate cleavage furrow formation. PLoS Biol 7, e1000110.10.1371/journal.pbio.1000110
[153] Wong, O.K., and Fang, G. (2005). Plx1 is the 3F3/2 kinase responsible for targeting spindle checkpoint proteins to kinetochores. J Cell Biol 170, 709-719 .10.1083/jcb.200502163
[154] Wu, Z.Q., and Liu, X. (2008). Role for Plk1 phosphorylation of Hbo1 in regulation of replication licensing. Proc Natl Acad Sci U S A 105, 1919-1924 .10.1073/pnas.0712063105
[155] Wu, Z.Q., Yang, X., Weber, G., and Liu, X. (2008). Plk1 phosphorylation of TRF1 is essential for its binding to telomeres. J Biol Chem 283, 25503-25513 .10.1074/jbc.M803304200
[156] Yang, X., Li, H., Liu, X.S., Deng, A., and Liu, X. (2009a). Cdc2-mediated phosphorylation of CLIP-170 is essential for its inhibition of centrosome reduplication. J Biol Chem 284, 28775-28782 .10.1074/jbc.M109.017681
[157] Yang, X., Li, H., Zhou, Z., Wang, W.H., Deng, A., Andrisani, O., and Liu, X. (2009b). Plk1-mediated phosphorylation of Topors regulates p53 stability. J Biol Chem 284, 18588-18592 .10.1074/jbc.C109.001560
[158] Yim, H., and Erikson, R.L. (2009). Polo-like kinase 1 depletion induces DNA damage in early S prior to caspase activation. Mol Cell Biol 29, 2609-2621 .10.1128/MCB.01277-08
[159] Yoo, H.Y., Kumagai, A., Shevchenko, A., Shevchenko, A., and Dunphy, W.G. (2004). Adaptation of a DNA replication checkpoint response depends upon inactivation of Claspin by the Polo-like kinase. Cell 117, 575-588 .10.1016/S0092-8674(04)00417-9
[160] Yuan, J., Eckerdt, F., Bereiter-Hahn, J., Kurunci-Csacsko, E., Kaufmann, M., and Strebhardt, K. (2002). Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene 21, 8282-8292 .10.1038/sj.onc.1206011
[161] Yüce, O., Piekny, A., and Glotzer, M. (2005). An ECT2-centralspindlin complex regulates the localization and function of RhoA. J Cell Biol 170, 571-582 .10.1083/jcb.200501097
[162] Zhao, W.M., and Fang, G. (2005). MgcRacGAP controls the assembly of the contractile ring and the initiation of cytokinesis. Proc Natl Acad Sci U S A 102, 13158-13163 .10.1073/pnas.0504145102
[163] Zhou, T., Aumais, J.P., Liu, X., Yu-Lee, L.-Y., and Erikson, R.L. (2003). A role for Plk1 phosphorylation of NudC in cytokinesis. Dev Cell 5, 127-138 .10.1016/S1534-5807(03)00186-2